PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16365879-7 2006 Furthermore, the UVB-dependent induction of 24-hydroxylase was blocked by the cytochrome-P450 inhibitor ketoconazole. Ketoconazole 104-116 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 78-93 20945304-0 2004 Human cytochrome P450: metabolism of testosterone by CYP3A4 and inhibition by ketoconazole. Ketoconazole 78-90 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 6-21 12599212-6 2003 On the other hand, we show that ketoconazole, a cytochrome P-450 inhibitor, hinders the wound closure induced by FCS in wounded 3T6 fibroblast cultures. Ketoconazole 32-44 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 48-64 12599212-7 2003 12 and 20 Hydroxyeicosatetraenoic acids (HETEs), which are key AA metabolites synthesized by cytochrome P-450, partially revert the effects of ketoconazole on the wound repair process. Ketoconazole 143-155 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 93-109 15618748-11 2003 ABT, SKF-525A, and ketoconazole showed different selectivity and had a wide range of Ki values for the drug oxidations catalyzed by human CYP enzymes. Ketoconazole 19-31 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 138-141 12388057-6 2003 We found that in high endothelial venular cells (SVEC4-10), multiple inhibitors of CYP450 monooxygenases (SKF-525a, ketoconazole, troleandomycin, itraconazole) attenuated TNF-alpha induction of MAdCAM-1, whereas NADPH oxidase inhibition (PR-39) did not. Ketoconazole 116-128 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 83-89 15618748-12 2003 Therefore, we conclude that inhibitory studies designed to predict the contribution of CYP enzymes to the metabolism of certain compounds should be performed using multiple CYP inhibitors, such as ABT, SKF-525A, and ketoconazole. Ketoconazole 216-228 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 87-90 9694927-12 1998 These potential dual actions on HERG currents suggest that precautions should be taken in long-term ketoconazole treatment, particularly for patients who have decreased liver function or are on a drug regimen requiring simultaneous medications that use cytochrome-P450 for breakdown, such as terfenadine or erythromycin, or Class III antiarrhythmic drugs. Ketoconazole 100-112 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 253-268 11869873-2 2002 The environmental pollutant 3-methylsulfonyl-DDE (3-MeSO2-DDE) and the cytochrome P450 (CYP) inhibitors ketoconazole, metyrapone and aminoglutethimide were studied for their effects on the steroid formation. Ketoconazole 104-116 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 88-91 11274000-9 2001 EDHF-mediated vasorelaxation, however, was sensitive to the phospholipase A(2) inhibitor oleyloxyethyl phosphorylcholine and the CYP450 inhibitor ketoconazole. Ketoconazole 146-158 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 129-135 7808019-8 1994 Both of these hypercatabolic states can be modulated by concurrent administration of ketoconazole, an inhibitor of cytochrome P-450 and lipoxygenase-mediated oxidations. Ketoconazole 85-97 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 115-148 9600717-6 1998 Ketoconazole, a relatively specific CYP 3A4 inhibitor, inhibited the reaction; the concentration resulting in 50% of maximum inhibition, IC50, was 0.15 microM and the inhibition constant, Ki, was < 0.04 microM in five of six livers tested. Ketoconazole 0-12 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 36-39 9600717-13 1998 Co-administration of adinazolam with CYP 3A4 inhibitors such as ketoconazole or erythromycin might lead to reduced efficacy, since adinazolam by itself has relatively weak benzodiazepine agonist activity, with much of the pharmacological activity of adinazolam being attributable to its active metabolite NDMAD. Ketoconazole 64-76 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 37-40 16535142-4 1995 Carbon monoxide saturation of the enzyme preparation and known mammalian cytochrome P-450 inhibitors such as quinidine HCl, ketoconazole, troleandomycin, and sulfaphenazole abolish the demethylating activity extensively. Ketoconazole 124-136 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 73-89 7967726-8 1994 Both of these hypercatabolic states can be modulated by concurrent administration of ketoconazole, an inhibitor of cytochrome P-450 and lipoxygenase-mediated oxidations. Ketoconazole 85-97 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 115-148 8068004-6 1994 Consistent with this idea, the imidazole cytochrome P-450 inhibitors miconazole, econazole, clotrimazole and ketoconazole inhibited the thapsigargin-elevated [Ca2+]i with pIC50 values of 7.1, 7.1, 7.1 and 5.8 respectively. Ketoconazole 109-121 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 41-57 7519397-1 1994 Ketoconazole, cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate, and gossypol are reported inhibitors of the lipoxygenase (LO) and cytochrome P-450 enzyme systems and are potent blockers of swelling-activated efflux of organic osmolytes and volume-sensitive anion channels in C6 glioma cells. Ketoconazole 0-12 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 125-141 8230282-4 1993 PURPOSE: We studied the clinical pharmacology of all-trans RA in cancer patients to determine possible mechanisms of acquired resistance and evaluated the potential for reversal by ketoconazole, an inhibitor of cytochrome-P450 oxidative enzymes. Ketoconazole 181-193 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 211-226 8230282-14 1993 Ketoconazole attenuates this accelerated catabolism, suggesting that oxidation by cytochrome-P450 enzymes is an important pathway for both constitutive and induced pathways of all-trans RA metabolism. Ketoconazole 0-12 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 82-97 1510705-3 1992 Ketoconazole, a known inhibitor of cytochrome P450 isozymes, caused marked inhibition of carboxyprimaquine formation with IC50 and K(i) values of 15 and 6.7 microM, respectively. Ketoconazole 0-12 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 35-50 8411129-1 1993 Inhibition of the metabolism of arachidonic acid by the epoxygenase (cytochrome P-450) pathway with the inhibitor ketoconazole results in excessive cell swelling upon exposure to hyposmolality instead of the rapid and complete regulatory volume decrease (RVD) normally observed. Ketoconazole 114-126 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 69-85 1458471-1 1992 The growth-inhibitory effects of ketoconazole, an antifungal agent which inhibits arachidonic acid lipoxygenases and cytochrome P-450 enzymes, were tested in human colon and breast cancer cell lines. Ketoconazole 33-45 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 117-133 1458471-8 1992 The results suggest that cytochrome P-450 enzyme(s) activity(ies) could be implicated in the antiproliferative effects of ketoconazole. Ketoconazole 122-134 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 25-41 1328295-6 1992 This cytochrome P-450 mediated activity was oxygen- and NADPH-dependent and was inhibited 68% by 5 microM ketoconazole (P = 0.0035, n = 8) and 51% by carbon monoxide (P = 0.02, n = 6). Ketoconazole 106-118 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 5-21 1596283-5 1992 The inhibition of ketoconazole, a known inhibitor of cytochrome P450 isozymes, and the dependency of metabolite formation on the presence of NADPH indicated that cytochrome P450 isozyme(s) catalysed metabolite production. Ketoconazole 18-30 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 53-68 1550407-4 1992 The synthesis of 1,25(OH)2D3 and 24,25(OH)2D3 by macrophages and fibroblast-like cells respectively was inhibited by ketoconazole, indicating that both hydroxylases are dependent on cytochrome P-450. Ketoconazole 117-129 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 182-198 1311943-7 1992 These data confirm that ketoconazole is a potent inhibitor of cytochrome P-450-IIIA4, and this has clinical relevance. Ketoconazole 24-36 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 62-84 1596283-5 1992 The inhibition of ketoconazole, a known inhibitor of cytochrome P450 isozymes, and the dependency of metabolite formation on the presence of NADPH indicated that cytochrome P450 isozyme(s) catalysed metabolite production. Ketoconazole 18-30 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 162-177 2214784-1 1990 An oral antimycotic agent, ketoconazole has been demonstrated to be an inhibitor of cytochrome P-450-dependent monooxygenases. Ketoconazole 27-39 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 84-100 1811554-2 1991 The hypothesis that the mechanism of action of gemfibrozil involved the cytochrome P-450 system was tested by using ketoconazole, a P-450 inhibitor, which blocks the formation of endogenous polar sterols. Ketoconazole 116-128 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 72-88 2214784-6 1990 From the binding mode of ketoconazole to cytochrome P-450 and the present findings, it appears likely that the agent binds to a site which is different from that of steroids or pyridine nucleotides. Ketoconazole 25-37 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 41-57 3111839-0 1987 Ketoconazole as a possible universal inhibitor of cytochrome P-450 dependent enzymes: its mode of inhibition. Ketoconazole 0-12 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 50-66 3036162-1 1987 Ketoconazole, an imidazole derivative, is a member of a class of metabolic inhibitors acting specifically at cytochrome-P450 mediated reactions. Ketoconazole 0-12 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 109-124 2775621-5 1989 By contrast, ketoconazole had a much smaller effect on the 0-8 h urinary metabolic ratio of debrisoquine, indicating that ketoconazole has a selective inhibitory effect on different forms of cytochrome P-450. Ketoconazole 122-134 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 191-207 2763709-1 1989 Oral therapy with nizoral and griseofulvin influences the system of cytochrome P = 450-dependent monoxygenases of the liver, this resulting in the depression of antipyrine microsomal oxidation. Ketoconazole 18-25 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 68-86 2848984-2 1988 The first compound was ketoconazole, a well-known inhibitor not only of fungal cytochrome P-450 but at higher concentrations also of mammalian cytochrome P-450 dependent enzymes. Ketoconazole 23-35 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 79-95 3111839-1 1987 Modes of inhibition and binding of ketoconazole, an orally antimycotic agent, to NADPH-cytochrome P-450 dependent enzymes were investigated using subcellular fractions of human and rat testes, human adrenocortical adenoma tissue and rat adrenals and livers. Ketoconazole 35-47 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 87-103 3111839-4 1987 Kinetic studies indicated that ketoconazole bound to cytochrome P-450 and not to other components of monooxygenase systems. Ketoconazole 31-43 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 53-69 3111839-5 1987 Spectrophotometric studies also revealed direct binding of ketoconazole to cytochrome P-450 component by inducing type II difference spectra in all tissue preparations examined, indicating that ketoconazole is possibly a universal inhibitor of NADPH-cytochrome P-450 dependent monooxygenases which are involved in metabolism of many substances including steroids, toxins, carcinogens and others. Ketoconazole 59-71 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 75-91 3111839-5 1987 Spectrophotometric studies also revealed direct binding of ketoconazole to cytochrome P-450 component by inducing type II difference spectra in all tissue preparations examined, indicating that ketoconazole is possibly a universal inhibitor of NADPH-cytochrome P-450 dependent monooxygenases which are involved in metabolism of many substances including steroids, toxins, carcinogens and others. Ketoconazole 59-71 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 250-266 3111839-5 1987 Spectrophotometric studies also revealed direct binding of ketoconazole to cytochrome P-450 component by inducing type II difference spectra in all tissue preparations examined, indicating that ketoconazole is possibly a universal inhibitor of NADPH-cytochrome P-450 dependent monooxygenases which are involved in metabolism of many substances including steroids, toxins, carcinogens and others. Ketoconazole 194-206 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 75-91 3111839-5 1987 Spectrophotometric studies also revealed direct binding of ketoconazole to cytochrome P-450 component by inducing type II difference spectra in all tissue preparations examined, indicating that ketoconazole is possibly a universal inhibitor of NADPH-cytochrome P-450 dependent monooxygenases which are involved in metabolism of many substances including steroids, toxins, carcinogens and others. Ketoconazole 194-206 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 250-266 3030012-10 1987 The interaction with mammalian cytochrome P-450 decreases from miconazole greater than ketoconazole much greater than itraconazole and is much weaker than the interaction of the antimycotics with yeast cytochrome P-450. Ketoconazole 87-99 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 31-47 3331377-3 1987 Representative examples of the above mechanisms are as following: (1) Ketoconazole possesses inhibitory effects in vitro on cytochrome P-450. Ketoconazole 70-82 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 124-140 3027305-8 1987 Etomidate, ketoconazole, miconazole and metyrapone inhibit cortisol biosynthesis in the human adrenal gland in different manners, which appear to involve the four cytochrome P-450-dependent monooxygenase reactions. Ketoconazole 11-23 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 163-179 3030012-10 1987 The interaction with mammalian cytochrome P-450 decreases from miconazole greater than ketoconazole much greater than itraconazole and is much weaker than the interaction of the antimycotics with yeast cytochrome P-450. Ketoconazole 87-99 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 202-218 28436281-2 2018 Roles of human cytochrome P450 (P450) 3A4 in oxidation of an antihistaminic drug terfenadine have been previously investigated in association with terfenadine-ketoconazole interaction. Ketoconazole 159-171 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 15-41 3025521-5 1986 Since ketoconazole is known to inhibit cytochrome P-450-dependent enzyme reactions, the results of the present study support the contention that cytochrome P-450 is involved in the aromatisation process. Ketoconazole 6-18 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 39-55 3025521-5 1986 Since ketoconazole is known to inhibit cytochrome P-450-dependent enzyme reactions, the results of the present study support the contention that cytochrome P-450 is involved in the aromatisation process. Ketoconazole 6-18 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 145-161 31278717-1 2019 Ketoconazole is a first orally available anti-fungal drug which has been reported as a potent inhibitor of human cytochrome P-450. Ketoconazole 0-12 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 113-129 30072626-6 2018 Based on the results for the formation of metabolites when incubated in dexamethasone-induced microsomes, incubation with ketoconazole, and human recombinant cDNA-expressed cytochrome P450s, we identified CYP3A4 and CYP3A5 as the major CYP isoforms involved in the hydroxylation of loxoprofen (M3 and M4). Ketoconazole 122-134 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 205-208 27718490-3 2016 METHODS: To overcome this drawback, the cross-reactivities exhibited by six chemical inhibitors (furafylline, montelukast, sulfaphenazole, ticlopidine, quinidine and ketoconazole) were quantified using specific CYP enzyme marker reactions. Ketoconazole 166-178 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 211-214 28185143-1 2017 BACKGROUND AND OBJECTIVES: 1-Aminobenzotriazole, a known time-dependent inhibitor of cytochrome P450 (CYP) enzymes, and ketoconazole, a strong inhibitor of the human CYP3A4 isozyme, are used as standard probe inhibitors to characterize the CYP and/or non-CYP-mediated metabolism of xenobiotics. Ketoconazole 120-132 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 102-105 28185143-1 2017 BACKGROUND AND OBJECTIVES: 1-Aminobenzotriazole, a known time-dependent inhibitor of cytochrome P450 (CYP) enzymes, and ketoconazole, a strong inhibitor of the human CYP3A4 isozyme, are used as standard probe inhibitors to characterize the CYP and/or non-CYP-mediated metabolism of xenobiotics. Ketoconazole 120-132 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 166-169 28185143-1 2017 BACKGROUND AND OBJECTIVES: 1-Aminobenzotriazole, a known time-dependent inhibitor of cytochrome P450 (CYP) enzymes, and ketoconazole, a strong inhibitor of the human CYP3A4 isozyme, are used as standard probe inhibitors to characterize the CYP and/or non-CYP-mediated metabolism of xenobiotics. Ketoconazole 120-132 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 166-169 24117377-7 2013 In contrast, the oxygen reduction current completely disappeared in the presence of the CYP inhibitor (ketoconazole). Ketoconazole 103-115 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 88-91 27063220-5 2016 Direct CYP inhibition was validated using 7 inhibitors (alpha-naphthoflavone, tranylcypromine, ticlopidine, fluconazole, quinidine, ketoconazole and 1-ABT). Ketoconazole 132-144 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 7-10 25864949-7 2015 The cytochrome P450 (CYP)-specific bioactivity of the liver microsomal film on the catalytically superior, stable HPG surface was confirmed by monitoring the electrocatalytic conversion of testosterone to 6beta-hydroxytestosterone and its inhibition by the CYP-specific ketoconazole inhibitor. Ketoconazole 270-282 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 4-19 25864949-7 2015 The cytochrome P450 (CYP)-specific bioactivity of the liver microsomal film on the catalytically superior, stable HPG surface was confirmed by monitoring the electrocatalytic conversion of testosterone to 6beta-hydroxytestosterone and its inhibition by the CYP-specific ketoconazole inhibitor. Ketoconazole 270-282 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 21-24 22426195-2 2013 A potential drug-drug interaction exists between docetaxel and ketoconazole because both agents are metabolized hepatically by the cytochrome P-450 system, and ketoconazole can inhibit p-gp efflux of docetaxel at blood brain barrier. Ketoconazole 63-75 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 131-147 20437462-6 2010 GLB depletion and metabolite formation in human liver microsomes were most significantly inhibited by the CYP3A inhibitor ketoconazole compared with the inhibitors of other CYP isoforms. Ketoconazole 122-134 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 106-109 21704641-8 2011 The correlations between CYP isoform-specific activities and CBD oxidative activities in 16 individual HLMs indicated that 6beta-OH- and 4""-OH-CBDs were mainly formed by CYP3A4, which was supported by inhibition studies using ketoconazole and an anti-CYP3A4 antibody. Ketoconazole 227-239 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 25-28